DYAI
Dyadic International, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.52
+3.89%Year over year
Reported trailing growth
- Revenue
- +1.5%
- EBITDA
- -41.4%
- EBIT
- -35.7%
- EPS
- -13.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +112.4%
- EBITDA
- +44.9%
- EPS
- +41.4%
Three-year CAGR
- Revenue
- -25.1%
- EBITDA
- -28.4%
- EBIT
- -21.1%
- Net income
- -26.8%
- EPS
- -15.0%
- Free cash flow
- -43.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026